IGF1 and metabolic disease: The metabolic and hepatic response to exogenous leptin treatment was associated with several factors, including the severity of metabolic disease at baseline, levels of triglycerides and triglyceride-rich apolipoproteins, baseline leptin levels, and changes in IGF-1 levels.